REDX PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.167 EUR | +67.00% |
|
-.--% | -30.42% |
| 17/06 | Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress | CI |
| 16/05 | Redx Pharma plc Appoints Claire Catherinet as Director | CI |
Valuation
| Fiscal Period: September | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 233 | 181.5 | 83.01 |
| Enterprise Value (EV) 1 | 220.8 | 145.9 | 82.6 |
| P/E ratio | -10.1 x | -8.9 x | -2.5 x |
| Yield | - | - | - |
| Capitalization / Revenue | 23.2 x | 9.71 x | 19.8 x |
| EV / Revenue | 22 x | 7.81 x | 19.7 x |
| EV / EBITDA | -11.3 x | -8.01 x | -2.7 x |
| EV / FCF | -14.3 x | -28.5 x | -3.68 x |
| FCF Yield | -7% | -3.51% | -27.2% |
| Price to Book | 17.7 x | 5.47 x | 24.7 x |
| Nbr of stocks (in thousands) | 2,75,282 | 3,33,353 | 3,34,911 |
| Reference price 2 | 0.8464 | 0.5444 | 0.2479 |
| Announcement Date | 11/02/22 | 16/02/23 | 16/02/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Settembre | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.129 | 3.131 | 5.685 | 10.04 | 18.69 | 4.202 |
| EBITDA 1 | -9.038 | -6.956 | -8.205 | -19.53 | -18.21 | -30.56 |
| EBIT 1 | -9.202 | -7.047 | -8.268 | -19.74 | -18.56 | -30.98 |
| Operating Margin | -7,133.33% | -225.07% | -145.44% | -196.76% | -99.32% | -737.27% |
| Earnings before Tax (EBT) 1 | -10.15 | -6.335 | -9.168 | -21.44 | -17.8 | -32.79 |
| Net income 1 | -8.845 | -4.318 | -9.213 | -21.58 | -18 | -33.16 |
| Net margin | -6,856.59% | -137.91% | -162.06% | -215.01% | -96.33% | -789.05% |
| EPS 2 | -0.0700 | -0.0341 | -0.0542 | -0.0841 | -0.0612 | -0.0990 |
| Free Cash Flow 1 | -14.85 | -2.747 | 1.588 | -15.47 | -5.118 | -22.47 |
| FCF margin | -11,513.86% | -87.74% | 27.94% | -154.14% | -27.38% | -534.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/11/18 | 16/03/20 | 27/01/21 | 11/02/22 | 16/02/23 | 16/02/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 6.47 | 3.24 | 7.04 | 12.2 | 35.5 | 0.41 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -14.9 | -2.75 | 1.59 | -15.5 | -5.12 | -22.5 |
| ROE (net income / shareholders' equity) | -88% | -119% | -441% | -285% | -77.5% | -181% |
| ROA (Net income/ Total Assets) | -30.3% | -52.8% | -25.9% | -34.1% | -22.7% | -43.9% |
| Assets 1 | 29.23 | 8.175 | 35.61 | 63.35 | 79.16 | 75.44 |
| Book Value Per Share 2 | 0.0500 | 0.0100 | 0.0100 | 0.0500 | 0.1000 | 0.0100 |
| Cash Flow per Share 2 | 0.0500 | 0.0300 | 0.1400 | 0.1100 | 0.1600 | 0.0500 |
| Capex 1 | 0.13 | 0.03 | 0.06 | 0.75 | 0.26 | 0.2 |
| Capex / Sales | 102.33% | 0.89% | 1.04% | 7.51% | 1.4% | 4.64% |
| Announcement Date | 29/11/18 | 16/03/20 | 27/01/21 | 11/02/22 | 16/02/23 | 16/02/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -30.42% | 70.6M | |
| +16.42% | 124B | |
| +19.02% | 112B | |
| +3.52% | 22.94B | |
| -11.63% | 17.02B | |
| -16.50% | 16.88B | |
| -39.57% | 16.87B | |
| +2.68% | 13.63B | |
| +21.16% | 11.61B | |
| +108.78% | 10.31B |
- Stock Market
- Equities
- 0RX Stock
- Financials Redx Pharma Plc
